SG Americas Securities LLC Has $22.33 Million Stock Holdings in Kiniksa Pharmaceuticals International, plc $KNSA

SG Americas Securities LLC lifted its position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 288.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 541,396 shares of the company’s stock after purchasing an additional 402,078 shares during the quarter. SG Americas Securities LLC’s holdings in Kiniksa Pharmaceuticals International were worth $22,333,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. EverSource Wealth Advisors LLC increased its position in shares of Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after buying an additional 532 shares in the last quarter. Mariner LLC lifted its holdings in Kiniksa Pharmaceuticals International by 5.8% during the third quarter. Mariner LLC now owns 13,253 shares of the company’s stock worth $515,000 after acquiring an additional 732 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in Kiniksa Pharmaceuticals International by 4.9% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 16,424 shares of the company’s stock valued at $701,000 after acquiring an additional 771 shares during the period. USA Financial Formulas acquired a new position in Kiniksa Pharmaceuticals International in the third quarter valued at about $32,000. Finally, Nordea Investment Management AB increased its holdings in shares of Kiniksa Pharmaceuticals International by 0.7% in the third quarter. Nordea Investment Management AB now owns 131,074 shares of the company’s stock worth $5,016,000 after acquiring an additional 914 shares in the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Insider Buying and Selling

In related news, Director Barry D. Quart sold 12,528 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $45.27, for a total value of $567,142.56. Following the transaction, the director directly owned 12,546 shares of the company’s stock, valued at $567,957.42. This trade represents a 49.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Mark Ragosa sold 17,845 shares of Kiniksa Pharmaceuticals International stock in a transaction on Monday, February 9th. The shares were sold at an average price of $43.28, for a total value of $772,331.60. Following the completion of the transaction, the chief financial officer owned 12,086 shares in the company, valued at approximately $523,082.08. The trade was a 59.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 48,605 shares of company stock worth $2,122,646 over the last three months. 53.48% of the stock is currently owned by insiders.

Kiniksa Pharmaceuticals International Trading Up 2.1%

NASDAQ KNSA opened at $46.78 on Friday. The company has a market cap of $3.58 billion, a price-to-earnings ratio of 63.22 and a beta of 0.06. The company has a 50 day moving average of $44.75 and a 200-day moving average of $41.40. Kiniksa Pharmaceuticals International, plc has a 1-year low of $18.25 and a 1-year high of $49.12.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, February 24th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.12). Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.The company had revenue of $202.13 million for the quarter, compared to analyst estimates of $200.86 million. During the same period in the prior year, the company earned ($0.12) EPS. The company’s quarterly revenue was up 65.0% compared to the same quarter last year. On average, equities research analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Analyst Ratings Changes

KNSA has been the topic of a number of research analyst reports. Zacks Research raised Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 25th. Wedbush boosted their price objective on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Thursday, January 22nd. Wells Fargo & Company increased their price target on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Finally, Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a “buy” rating to a “hold” rating in a research note on Saturday, March 14th. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $55.29.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.